Urea-cycle disorders as a paradigm for inborn errors of hepatocyte metabolism

Leonard, 2002, Urea cycle disorders, Semin. Neonatol., 7, 27, 10.1053/siny.2001.0085 Nicolaides, 2002, Neurological outcome of patients with ornithine carbamoyltransferase deficiency, Arch. Dis. Child., 86, 54, 10.1136/adc.86.1.54 Summar, 2001, Proceedings of a consensus conference for the management of patients with urea cycle disorders, J. Pediatr., 138, S6, 10.1067/mpd.2001.111831 Scaglia, 2002, An integrated approach to the diagnosis and prospective management of partial ornithine transcarbamylase deficiency, Pediatrics, 109, 150, 10.1542/peds.109.1.150 Brusilow, 2001, Urea cycle enzymes, 1909 Tuchman, 2000, The molecular basis of ornithine transcarbamylase deficiency, Eur. J. Pediatr., 159, S196, 10.1007/PL00014402 Butterworth, 2001, Glutamate transporter and receptor function in disorders of ammonia metabolism, Ment. Retard. Dev. Disabil. Res. Rev., 7, 276, 10.1002/mrdd.1038 Lennie, 1995, Body energy status and the metabolic response to acute inflammation, Am. J. Physiol., 269, R1024 Steiner, 2001, Laboratory evaluation of urea cycle disorders, J. Pediatr., 138, S21, 10.1067/mpd.2001.111833 Riudor, 2000, Influence of dose and age on the response of the allopurinol test for ornithine carbamoyltransferase deficiency in control infants, J. Inherit. Metab. Dis., 23, 662, 10.1023/A:1005610325170 Potter, 2001, Ornithine carbamoyltransferase deficiency: improved sensitivity of testing for protein tolerance in the diagnosis of heterozygotes, J. Inherit. Metab. Dis., 24, 5, 10.1023/A:1005682017337 Tuchman, 2002, Mutations and polymorphisms in the human ornithine transcarbamylase gene, Hum. Mutat., 19, 93, 10.1002/humu.10035 McCullough, 2000, Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype, Am. J. Med. Genet., 93, 313, 10.1002/1096-8628(20000814)93:4<313::AID-AJMG11>3.0.CO;2-M Tuchman, 1999, Blood levels of ammonia and nitrogen scavenging amino acids in patients with inherited hyperammonemia, Mol. Genet. Metab., 66, 10, 10.1006/mgme.1998.2783 Yudkoff, 1996, In vivo nitrogen metabolism in ornithine transcarbamylase deficiency, J. Clin. Invest., 98, 2167, 10.1172/JCI119023 Lee, 2000, In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle, Proc. Natl. Acad. Sci. U. S. A., 97, 8021, 10.1073/pnas.140082197 Summar, 2001, Current strategies for the management of neonatal urea cycle disorders, J. Pediatr., 138, S30, 10.1067/mpd.2001.111834 Burlina, 2001, Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients, Mol. Genet. Metab., 72, 351, 10.1006/mgme.2001.3156 Maestri, 1999, Neonatal onset ornithine transcarbamylase deficiency: a retrospective analysis, J. Pediatr., 134, 268, 10.1016/S0022-3476(99)70448-8 Maestri, 1996, Long-term treatment of girls with ornithine transcarbamylase deficiency, N. Engl. J. Med., 335, 855, 10.1056/NEJM199609193351204 Scaglia G. et al. Differential utilization of systemic and enteral ammonia for urea synthesis in control subjects and carriers for ornithine transcarbamylase deficiency. Am. J. Clin. Nutr. (in press) Lee, 2001, Long-term correction of urea cycle disorders, J. Pediatr., 138, S62, 10.1067/mpd.2001.111838 Batshaw, 1999, Correction of ureagenesis after gene transfer in an animal model and after liver transplantation in humans with ornithine transcarbamylase deficiency, Pediatr. Res., 46, 588, 10.1203/00006450-199911000-00016 Saudubray, 1999, Liver transplantation in urea cycle disorders, Eur. J. Pediatr., 158, S55, 10.1007/PL00014323 Ye, 1996, Prolonged metabolic correction in adult ornithine transcarbamylase – deficient mice with adenoviral vectors, J. Biol. Chem., 271, 3639, 10.1074/jbc.271.7.3639 Lee, 1999, Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia, Proc. Natl. Acad. Sci. U. S. A., 96, 3981, 10.1073/pnas.96.7.3981 Patejunas, 1998, Evaluation of gene therapy for citrullinaemia using murine and bovine models, J. Inherit. Metab. Dis., 21, 138, 10.1023/A:1005322010854 Ye, 2000, Correction of argininosuccinate synthetase (AS) deficiency in a murine model of citrullinemia with recombinant adenovirus carrying human AS cDNA, Gene Ther., 7, 1777, 10.1038/sj.gt.3301303 Brenner, 1999, Gene transfer by adenovectors, Blood, 94, 3965, 10.1182/blood.V94.12.3965 O'Neal, 1998, Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing α1-antitrypsin after systemic delivery, Hum. Gene Ther., 9, 1587, 10.1089/hum.1998.9.11-1587 Morral, 2002, Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons, Hum. Gene Ther., 13, 143, 10.1089/10430340152712692 Zimmer, 1999, Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency, Mol. Med., 5, 244, 10.1007/BF03402122 Ye, 2001, Differences in the human and mouse amino-terminal leader peptides of ornithine transcarbamylase affect mitochondrial import and efficacy of adenoviral vectors, Hum. Gene Ther., 12, 1035, 10.1089/104303401750214267 Raper, 2002, A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency, Hum. Gene Ther., 13, 163, 10.1089/10430340152712719 Roy-Chowdhury, 2002, Evolution of adenoviruses as gene therapy vectors, Mol. Ther., 5, 340, 10.1006/mthe.2001.0575 Kochanek, 1999, High-capacity adenoviral vectors for gene transfer and somatic gene therapy, Hum. Gene Ther., 10, 2451, 10.1089/10430349950016807 Kochanek, 2001, High-capacity ‘gutless’ adenoviral vectors, Curr. Opin. Mol. Ther., 3, 454 Pastore, 1999, Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors, Hum. Gene Ther., 10, 1773, 10.1089/10430349950017455 Glover, 2002, Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity, Mol. Ther., 5, 509, 10.1006/mthe.2002.0588 Loeb, 1999, Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy, Hum. Gene Ther., 10, 2295, 10.1089/10430349950016942 Morral, 1999, Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons, Proc. Natl. Acad. Sci. U. S. A., 96, 12816, 10.1073/pnas.96.22.12816 Ye, 2000, Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse, Gene Ther., 7, 1761, 10.1038/sj.gt.3301299 Saheki, 2002, Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD), J. Hum. Genet., 47, 333, 10.1007/s100380200046 Kobayashi, 1999, The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein, Nat. Genet., 22, 159, 10.1038/9667 Palacin, 2001, The molecular bases of cystinuria and lysinuric protein intolerance, Curr. Opin. Genet. Dev., 11, 328, 10.1016/S0959-437X(00)00198-2 Camacho, 1999, Hyperornithinaemia–hyperammonaemia–homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter, Nat. Genet., 22, 151, 10.1038/9658 Morris, 2002, Regulation of enzymes of the urea cycle and arginine metabolism, Annu. Rev. Nutr., 22, 87, 10.1146/annurev.nutr.22.110801.140547 Pearson, 2001, Neonatal pulmonary hypertension–urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function, N. Engl. J. Med., 344, 1832, 10.1056/NEJM200106143442404